following a full submission assessed under the end of life and orphan equivalent medicine process:
brexucabtagene autoleucel (Tecartus®) is accepted for use within NHSScotland.
Indication under review: Treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
In a single-arm, open-label, phase I/II study in patients with relapsed or refractory (R/R) ALL who received brexucabtagene autoleucel, overall complete remission rate was 71%.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice982KB (PDF)
- Medicine name:
- brexucabtagene autoleucel (Tecartus)
- SMC ID:
Treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 October 2023